nodes	percent_of_prediction	percent_of_DWPC	metapath
Ifosfamide—Cyclophosphamide—Mechlorethamine—lymphatic system cancer	0.336	1	CrCrCtD
Ifosfamide—Alkylating Activity—Mechlorethamine—lymphatic system cancer	0.314	0.591	CiPCiCtD
Ifosfamide—Alkylating Activity—Carmustine—lymphatic system cancer	0.217	0.409	CiPCiCtD
Ifosfamide—CYP3A5—Teniposide—lymphatic system cancer	0.013	0.182	CbGbCtD
Ifosfamide—CYP2C19—Teniposide—lymphatic system cancer	0.0105	0.147	CbGbCtD
Ifosfamide—CYP2C9—Teniposide—lymphatic system cancer	0.00874	0.122	CbGbCtD
Ifosfamide—CYP3A7—Vincristine—lymphatic system cancer	0.00836	0.117	CbGbCtD
Ifosfamide—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.00836	0.117	CbGbCtD
Ifosfamide—CYP3A5—Vincristine—lymphatic system cancer	0.00627	0.0877	CbGbCtD
Ifosfamide—CYP3A4—Cytarabine—lymphatic system cancer	0.00516	0.0721	CbGbCtD
Ifosfamide—CYP3A4—Teniposide—lymphatic system cancer	0.00508	0.0711	CbGbCtD
Ifosfamide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.00355	0.0497	CbGbCtD
Ifosfamide—CYP3A4—Vincristine—lymphatic system cancer	0.00245	0.0342	CbGbCtD
Ifosfamide—Depressed level of consciousness—Methotrexate—lymphatic system cancer	4.48e-05	0.00073	CcSEcCtD
Ifosfamide—Cardiac disorder—Vincristine—lymphatic system cancer	4.46e-05	0.000726	CcSEcCtD
Ifosfamide—Alopecia—Carmustine—lymphatic system cancer	4.45e-05	0.000724	CcSEcCtD
Ifosfamide—Skin exfoliation—Methotrexate—lymphatic system cancer	4.43e-05	0.000722	CcSEcCtD
Ifosfamide—Body temperature increased—Fludarabine—lymphatic system cancer	4.42e-05	0.000719	CcSEcCtD
Ifosfamide—Mental disorder—Carmustine—lymphatic system cancer	4.41e-05	0.000718	CcSEcCtD
Ifosfamide—Erythema—Carmustine—lymphatic system cancer	4.38e-05	0.000713	CcSEcCtD
Ifosfamide—Malnutrition—Carmustine—lymphatic system cancer	4.38e-05	0.000713	CcSEcCtD
Ifosfamide—Cough—Bleomycin—lymphatic system cancer	4.38e-05	0.000713	CcSEcCtD
Ifosfamide—Angiopathy—Vincristine—lymphatic system cancer	4.36e-05	0.00071	CcSEcCtD
Ifosfamide—Diarrhoea—Teniposide—lymphatic system cancer	4.35e-05	0.000708	CcSEcCtD
Ifosfamide—Mediastinal disorder—Vincristine—lymphatic system cancer	4.33e-05	0.000705	CcSEcCtD
Ifosfamide—Chest pain—Bleomycin—lymphatic system cancer	4.27e-05	0.000696	CcSEcCtD
Ifosfamide—Myalgia—Bleomycin—lymphatic system cancer	4.27e-05	0.000696	CcSEcCtD
Ifosfamide—Alopecia—Vincristine—lymphatic system cancer	4.25e-05	0.000691	CcSEcCtD
Ifosfamide—Coma—Methotrexate—lymphatic system cancer	4.24e-05	0.000691	CcSEcCtD
Ifosfamide—Discomfort—Bleomycin—lymphatic system cancer	4.22e-05	0.000687	CcSEcCtD
Ifosfamide—Mental disorder—Vincristine—lymphatic system cancer	4.21e-05	0.000685	CcSEcCtD
Ifosfamide—Chills—Mitoxantrone—lymphatic system cancer	4.2e-05	0.000684	CcSEcCtD
Ifosfamide—Neoplasm—Methotrexate—lymphatic system cancer	4.2e-05	0.000683	CcSEcCtD
Ifosfamide—Urine output increased—Methotrexate—lymphatic system cancer	4.2e-05	0.000683	CcSEcCtD
Ifosfamide—Arrhythmia—Mitoxantrone—lymphatic system cancer	4.18e-05	0.000681	CcSEcCtD
Ifosfamide—Alopecia—Mitoxantrone—lymphatic system cancer	4.13e-05	0.000673	CcSEcCtD
Ifosfamide—Pulmonary oedema—Methotrexate—lymphatic system cancer	4.13e-05	0.000673	CcSEcCtD
Ifosfamide—Confusional state—Bleomycin—lymphatic system cancer	4.13e-05	0.000673	CcSEcCtD
Ifosfamide—Vision blurred—Carmustine—lymphatic system cancer	4.13e-05	0.000672	CcSEcCtD
Ifosfamide—Hypersensitivity—Fludarabine—lymphatic system cancer	4.12e-05	0.00067	CcSEcCtD
Ifosfamide—Anaphylactic shock—Bleomycin—lymphatic system cancer	4.1e-05	0.000667	CcSEcCtD
Ifosfamide—Oedema—Bleomycin—lymphatic system cancer	4.1e-05	0.000667	CcSEcCtD
Ifosfamide—Erythema—Mitoxantrone—lymphatic system cancer	4.07e-05	0.000663	CcSEcCtD
Ifosfamide—Infection—Bleomycin—lymphatic system cancer	4.07e-05	0.000663	CcSEcCtD
Ifosfamide—Anaemia—Carmustine—lymphatic system cancer	4.05e-05	0.000659	CcSEcCtD
Ifosfamide—Vomiting—Teniposide—lymphatic system cancer	4.04e-05	0.000658	CcSEcCtD
Ifosfamide—Sepsis—Methotrexate—lymphatic system cancer	4.03e-05	0.000656	CcSEcCtD
Ifosfamide—Agitation—Carmustine—lymphatic system cancer	4.03e-05	0.000656	CcSEcCtD
Ifosfamide—Thrombocytopenia—Bleomycin—lymphatic system cancer	4.01e-05	0.000653	CcSEcCtD
Ifosfamide—Asthenia—Fludarabine—lymphatic system cancer	4.01e-05	0.000653	CcSEcCtD
Ifosfamide—Rash—Teniposide—lymphatic system cancer	4.01e-05	0.000653	CcSEcCtD
Ifosfamide—Dermatitis—Teniposide—lymphatic system cancer	4e-05	0.000652	CcSEcCtD
Ifosfamide—Pruritus—Fludarabine—lymphatic system cancer	3.95e-05	0.000644	CcSEcCtD
Ifosfamide—Leukopenia—Carmustine—lymphatic system cancer	3.92e-05	0.000639	CcSEcCtD
Ifosfamide—Anorexia—Bleomycin—lymphatic system cancer	3.9e-05	0.000636	CcSEcCtD
Ifosfamide—Thrombophlebitis—Methotrexate—lymphatic system cancer	3.89e-05	0.000634	CcSEcCtD
Ifosfamide—Anaemia—Vincristine—lymphatic system cancer	3.87e-05	0.000629	CcSEcCtD
Ifosfamide—Agitation—Vincristine—lymphatic system cancer	3.84e-05	0.000626	CcSEcCtD
Ifosfamide—Vision blurred—Mitoxantrone—lymphatic system cancer	3.84e-05	0.000625	CcSEcCtD
Ifosfamide—Polyuria—Methotrexate—lymphatic system cancer	3.84e-05	0.000625	CcSEcCtD
Ifosfamide—Hypotension—Bleomycin—lymphatic system cancer	3.83e-05	0.000623	CcSEcCtD
Ifosfamide—Diarrhoea—Fludarabine—lymphatic system cancer	3.82e-05	0.000622	CcSEcCtD
Ifosfamide—Convulsion—Carmustine—lymphatic system cancer	3.8e-05	0.000618	CcSEcCtD
Ifosfamide—Hypertension—Carmustine—lymphatic system cancer	3.78e-05	0.000616	CcSEcCtD
Ifosfamide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	3.78e-05	0.000615	CcSEcCtD
Ifosfamide—Nausea—Teniposide—lymphatic system cancer	3.78e-05	0.000615	CcSEcCtD
Ifosfamide—Anaemia—Mitoxantrone—lymphatic system cancer	3.76e-05	0.000613	CcSEcCtD
Ifosfamide—Vertigo—Vincristine—lymphatic system cancer	3.76e-05	0.000612	CcSEcCtD
Ifosfamide—Hepatic failure—Methotrexate—lymphatic system cancer	3.75e-05	0.000611	CcSEcCtD
Ifosfamide—Leukopenia—Vincristine—lymphatic system cancer	3.74e-05	0.00061	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	3.73e-05	0.000608	CcSEcCtD
Ifosfamide—Chest pain—Carmustine—lymphatic system cancer	3.73e-05	0.000607	CcSEcCtD
Ifosfamide—Myalgia—Carmustine—lymphatic system cancer	3.73e-05	0.000607	CcSEcCtD
Ifosfamide—Paraesthesia—Bleomycin—lymphatic system cancer	3.68e-05	0.000599	CcSEcCtD
Ifosfamide—Malaise—Mitoxantrone—lymphatic system cancer	3.67e-05	0.000598	CcSEcCtD
Ifosfamide—Dyspnoea—Bleomycin—lymphatic system cancer	3.65e-05	0.000595	CcSEcCtD
Ifosfamide—Renal failure acute—Methotrexate—lymphatic system cancer	3.65e-05	0.000594	CcSEcCtD
Ifosfamide—Leukopenia—Mitoxantrone—lymphatic system cancer	3.65e-05	0.000594	CcSEcCtD
Ifosfamide—Convulsion—Vincristine—lymphatic system cancer	3.62e-05	0.00059	CcSEcCtD
Ifosfamide—Hypertension—Vincristine—lymphatic system cancer	3.61e-05	0.000588	CcSEcCtD
Ifosfamide—Confusional state—Carmustine—lymphatic system cancer	3.61e-05	0.000587	CcSEcCtD
Ifosfamide—Oedema—Carmustine—lymphatic system cancer	3.58e-05	0.000582	CcSEcCtD
Ifosfamide—Decreased appetite—Bleomycin—lymphatic system cancer	3.56e-05	0.00058	CcSEcCtD
Ifosfamide—Myalgia—Vincristine—lymphatic system cancer	3.56e-05	0.00058	CcSEcCtD
Ifosfamide—Cough—Mitoxantrone—lymphatic system cancer	3.55e-05	0.000579	CcSEcCtD
Ifosfamide—Infection—Carmustine—lymphatic system cancer	3.55e-05	0.000578	CcSEcCtD
Ifosfamide—Vomiting—Fludarabine—lymphatic system cancer	3.55e-05	0.000578	CcSEcCtD
Ifosfamide—Convulsion—Mitoxantrone—lymphatic system cancer	3.53e-05	0.000575	CcSEcCtD
Ifosfamide—Rash—Fludarabine—lymphatic system cancer	3.52e-05	0.000574	CcSEcCtD
Ifosfamide—Dermatitis—Fludarabine—lymphatic system cancer	3.52e-05	0.000573	CcSEcCtD
Ifosfamide—Hypertension—Mitoxantrone—lymphatic system cancer	3.52e-05	0.000573	CcSEcCtD
Ifosfamide—Pain—Bleomycin—lymphatic system cancer	3.5e-05	0.00057	CcSEcCtD
Ifosfamide—Thrombocytopenia—Carmustine—lymphatic system cancer	3.5e-05	0.00057	CcSEcCtD
Ifosfamide—Myalgia—Mitoxantrone—lymphatic system cancer	3.47e-05	0.000565	CcSEcCtD
Ifosfamide—Arthralgia—Mitoxantrone—lymphatic system cancer	3.47e-05	0.000565	CcSEcCtD
Ifosfamide—Chest pain—Mitoxantrone—lymphatic system cancer	3.47e-05	0.000565	CcSEcCtD
Ifosfamide—Discomfort—Mitoxantrone—lymphatic system cancer	3.43e-05	0.000558	CcSEcCtD
Ifosfamide—Anaphylactic shock—Vincristine—lymphatic system cancer	3.41e-05	0.000556	CcSEcCtD
Ifosfamide—Oedema—Vincristine—lymphatic system cancer	3.41e-05	0.000556	CcSEcCtD
Ifosfamide—Anorexia—Carmustine—lymphatic system cancer	3.41e-05	0.000555	CcSEcCtD
Ifosfamide—Infection—Vincristine—lymphatic system cancer	3.39e-05	0.000552	CcSEcCtD
Ifosfamide—Feeling abnormal—Bleomycin—lymphatic system cancer	3.38e-05	0.00055	CcSEcCtD
Ifosfamide—Osteoarthritis—Methotrexate—lymphatic system cancer	3.37e-05	0.000549	CcSEcCtD
Ifosfamide—Confusional state—Mitoxantrone—lymphatic system cancer	3.35e-05	0.000546	CcSEcCtD
Ifosfamide—Nervous system disorder—Vincristine—lymphatic system cancer	3.35e-05	0.000545	CcSEcCtD
Ifosfamide—Thrombocytopenia—Vincristine—lymphatic system cancer	3.34e-05	0.000544	CcSEcCtD
Ifosfamide—Hypotension—Carmustine—lymphatic system cancer	3.34e-05	0.000544	CcSEcCtD
Ifosfamide—Oedema—Mitoxantrone—lymphatic system cancer	3.32e-05	0.000541	CcSEcCtD
Ifosfamide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	3.32e-05	0.000541	CcSEcCtD
Ifosfamide—Nausea—Fludarabine—lymphatic system cancer	3.32e-05	0.00054	CcSEcCtD
Ifosfamide—Infection—Mitoxantrone—lymphatic system cancer	3.3e-05	0.000538	CcSEcCtD
Ifosfamide—Hyperhidrosis—Vincristine—lymphatic system cancer	3.3e-05	0.000537	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	3.26e-05	0.00053	CcSEcCtD
Ifosfamide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	3.25e-05	0.00053	CcSEcCtD
Ifosfamide—Urticaria—Bleomycin—lymphatic system cancer	3.25e-05	0.00053	CcSEcCtD
Ifosfamide—Anorexia—Vincristine—lymphatic system cancer	3.25e-05	0.00053	CcSEcCtD
Ifosfamide—Body temperature increased—Bleomycin—lymphatic system cancer	3.24e-05	0.000527	CcSEcCtD
Ifosfamide—Skin disorder—Mitoxantrone—lymphatic system cancer	3.23e-05	0.000526	CcSEcCtD
Ifosfamide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	3.21e-05	0.000523	CcSEcCtD
Ifosfamide—Paraesthesia—Carmustine—lymphatic system cancer	3.21e-05	0.000523	CcSEcCtD
Ifosfamide—Hypotension—Vincristine—lymphatic system cancer	3.19e-05	0.000519	CcSEcCtD
Ifosfamide—Dyspnoea—Carmustine—lymphatic system cancer	3.19e-05	0.000519	CcSEcCtD
Ifosfamide—Somnolence—Carmustine—lymphatic system cancer	3.18e-05	0.000518	CcSEcCtD
Ifosfamide—Anorexia—Mitoxantrone—lymphatic system cancer	3.17e-05	0.000516	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	3.11e-05	0.000506	CcSEcCtD
Ifosfamide—Decreased appetite—Carmustine—lymphatic system cancer	3.11e-05	0.000506	CcSEcCtD
Ifosfamide—Hypotension—Mitoxantrone—lymphatic system cancer	3.11e-05	0.000506	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	3.09e-05	0.000503	CcSEcCtD
Ifosfamide—Paraesthesia—Vincristine—lymphatic system cancer	3.06e-05	0.000499	CcSEcCtD
Ifosfamide—Constipation—Carmustine—lymphatic system cancer	3.06e-05	0.000498	CcSEcCtD
Ifosfamide—Pain—Carmustine—lymphatic system cancer	3.06e-05	0.000498	CcSEcCtD
Ifosfamide—Breast disorder—Methotrexate—lymphatic system cancer	3.04e-05	0.000496	CcSEcCtD
Ifosfamide—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	3.03e-05	0.000494	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	3.03e-05	0.000493	CcSEcCtD
Ifosfamide—Hypersensitivity—Bleomycin—lymphatic system cancer	3.02e-05	0.000491	CcSEcCtD
Ifosfamide—Paraesthesia—Mitoxantrone—lymphatic system cancer	2.98e-05	0.000486	CcSEcCtD
Ifosfamide—Decreased appetite—Vincristine—lymphatic system cancer	2.97e-05	0.000483	CcSEcCtD
Ifosfamide—Dyspnoea—Mitoxantrone—lymphatic system cancer	2.96e-05	0.000483	CcSEcCtD
Ifosfamide—Somnolence—Mitoxantrone—lymphatic system cancer	2.95e-05	0.000481	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	2.95e-05	0.00048	CcSEcCtD
Ifosfamide—Feeling abnormal—Carmustine—lymphatic system cancer	2.95e-05	0.00048	CcSEcCtD
Ifosfamide—Fatigue—Vincristine—lymphatic system cancer	2.94e-05	0.000479	CcSEcCtD
Ifosfamide—Asthenia—Bleomycin—lymphatic system cancer	2.94e-05	0.000479	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Carmustine—lymphatic system cancer	2.92e-05	0.000476	CcSEcCtD
Ifosfamide—Constipation—Vincristine—lymphatic system cancer	2.92e-05	0.000475	CcSEcCtD
Ifosfamide—Pain—Vincristine—lymphatic system cancer	2.92e-05	0.000475	CcSEcCtD
Ifosfamide—Pruritus—Bleomycin—lymphatic system cancer	2.9e-05	0.000472	CcSEcCtD
Ifosfamide—Decreased appetite—Mitoxantrone—lymphatic system cancer	2.89e-05	0.000471	CcSEcCtD
Ifosfamide—Fatigue—Mitoxantrone—lymphatic system cancer	2.87e-05	0.000467	CcSEcCtD
Ifosfamide—Pancreatitis—Methotrexate—lymphatic system cancer	2.86e-05	0.000465	CcSEcCtD
Ifosfamide—Constipation—Mitoxantrone—lymphatic system cancer	2.84e-05	0.000463	CcSEcCtD
Ifosfamide—Pain—Mitoxantrone—lymphatic system cancer	2.84e-05	0.000463	CcSEcCtD
Ifosfamide—Abdominal pain—Carmustine—lymphatic system cancer	2.83e-05	0.00046	CcSEcCtD
Ifosfamide—Body temperature increased—Carmustine—lymphatic system cancer	2.83e-05	0.00046	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Vincristine—lymphatic system cancer	2.79e-05	0.000454	CcSEcCtD
Ifosfamide—Pancytopenia—Methotrexate—lymphatic system cancer	2.77e-05	0.00045	CcSEcCtD
Ifosfamide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	2.74e-05	0.000446	CcSEcCtD
Ifosfamide—Dysuria—Methotrexate—lymphatic system cancer	2.72e-05	0.000443	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	2.72e-05	0.000443	CcSEcCtD
Ifosfamide—Abdominal pain—Vincristine—lymphatic system cancer	2.7e-05	0.000439	CcSEcCtD
Ifosfamide—Body temperature increased—Vincristine—lymphatic system cancer	2.7e-05	0.000439	CcSEcCtD
Ifosfamide—Urticaria—Mitoxantrone—lymphatic system cancer	2.64e-05	0.00043	CcSEcCtD
Ifosfamide—Hypersensitivity—Carmustine—lymphatic system cancer	2.63e-05	0.000429	CcSEcCtD
Ifosfamide—Body temperature increased—Mitoxantrone—lymphatic system cancer	2.63e-05	0.000428	CcSEcCtD
Ifosfamide—Abdominal pain—Mitoxantrone—lymphatic system cancer	2.63e-05	0.000428	CcSEcCtD
Ifosfamide—Pneumonia—Methotrexate—lymphatic system cancer	2.61e-05	0.000425	CcSEcCtD
Ifosfamide—Vomiting—Bleomycin—lymphatic system cancer	2.6e-05	0.000424	CcSEcCtD
Ifosfamide—Infestation NOS—Methotrexate—lymphatic system cancer	2.6e-05	0.000423	CcSEcCtD
Ifosfamide—Infestation—Methotrexate—lymphatic system cancer	2.6e-05	0.000423	CcSEcCtD
Ifosfamide—Rash—Bleomycin—lymphatic system cancer	2.58e-05	0.000421	CcSEcCtD
Ifosfamide—Dermatitis—Bleomycin—lymphatic system cancer	2.58e-05	0.00042	CcSEcCtD
Ifosfamide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	2.57e-05	0.000419	CcSEcCtD
Ifosfamide—Asthenia—Carmustine—lymphatic system cancer	2.57e-05	0.000418	CcSEcCtD
Ifosfamide—Renal failure—Methotrexate—lymphatic system cancer	2.55e-05	0.000416	CcSEcCtD
Ifosfamide—Stomatitis—Methotrexate—lymphatic system cancer	2.53e-05	0.000412	CcSEcCtD
Ifosfamide—Conjunctivitis—Methotrexate—lymphatic system cancer	2.52e-05	0.000411	CcSEcCtD
Ifosfamide—Hypersensitivity—Vincristine—lymphatic system cancer	2.51e-05	0.000409	CcSEcCtD
Ifosfamide—Haematuria—Methotrexate—lymphatic system cancer	2.48e-05	0.000403	CcSEcCtD
Ifosfamide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	2.46e-05	0.0004	CcSEcCtD
Ifosfamide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	2.45e-05	0.000399	CcSEcCtD
Ifosfamide—Asthenia—Vincristine—lymphatic system cancer	2.45e-05	0.000399	CcSEcCtD
Ifosfamide—Diarrhoea—Carmustine—lymphatic system cancer	2.45e-05	0.000398	CcSEcCtD
Ifosfamide—Nausea—Bleomycin—lymphatic system cancer	2.43e-05	0.000396	CcSEcCtD
Ifosfamide—Agranulocytosis—Methotrexate—lymphatic system cancer	2.42e-05	0.000395	CcSEcCtD
Ifosfamide—Asthenia—Mitoxantrone—lymphatic system cancer	2.38e-05	0.000388	CcSEcCtD
Ifosfamide—Dizziness—Carmustine—lymphatic system cancer	2.36e-05	0.000385	CcSEcCtD
Ifosfamide—Haemoglobin—Methotrexate—lymphatic system cancer	2.34e-05	0.000382	CcSEcCtD
Ifosfamide—Diarrhoea—Vincristine—lymphatic system cancer	2.34e-05	0.00038	CcSEcCtD
Ifosfamide—Haemorrhage—Methotrexate—lymphatic system cancer	2.33e-05	0.00038	CcSEcCtD
Ifosfamide—Hepatitis—Methotrexate—lymphatic system cancer	2.33e-05	0.00038	CcSEcCtD
Ifosfamide—Urinary tract disorder—Methotrexate—lymphatic system cancer	2.3e-05	0.000375	CcSEcCtD
Ifosfamide—Urethral disorder—Methotrexate—lymphatic system cancer	2.28e-05	0.000372	CcSEcCtD
Ifosfamide—Diarrhoea—Mitoxantrone—lymphatic system cancer	2.27e-05	0.00037	CcSEcCtD
Ifosfamide—Vomiting—Carmustine—lymphatic system cancer	2.27e-05	0.00037	CcSEcCtD
Ifosfamide—Dizziness—Vincristine—lymphatic system cancer	2.26e-05	0.000368	CcSEcCtD
Ifosfamide—Rash—Carmustine—lymphatic system cancer	2.25e-05	0.000367	CcSEcCtD
Ifosfamide—Dermatitis—Carmustine—lymphatic system cancer	2.25e-05	0.000367	CcSEcCtD
Ifosfamide—Visual impairment—Methotrexate—lymphatic system cancer	2.25e-05	0.000366	CcSEcCtD
Ifosfamide—Erythema multiforme—Methotrexate—lymphatic system cancer	2.2e-05	0.000359	CcSEcCtD
Ifosfamide—Eye disorder—Methotrexate—lymphatic system cancer	2.18e-05	0.000355	CcSEcCtD
Ifosfamide—Tinnitus—Methotrexate—lymphatic system cancer	2.17e-05	0.000354	CcSEcCtD
Ifosfamide—Vomiting—Vincristine—lymphatic system cancer	2.17e-05	0.000353	CcSEcCtD
Ifosfamide—Cardiac disorder—Methotrexate—lymphatic system cancer	2.16e-05	0.000352	CcSEcCtD
Ifosfamide—Rash—Vincristine—lymphatic system cancer	2.15e-05	0.00035	CcSEcCtD
Ifosfamide—Dermatitis—Vincristine—lymphatic system cancer	2.15e-05	0.00035	CcSEcCtD
Ifosfamide—Nausea—Carmustine—lymphatic system cancer	2.12e-05	0.000346	CcSEcCtD
Ifosfamide—Angiopathy—Methotrexate—lymphatic system cancer	2.11e-05	0.000344	CcSEcCtD
Ifosfamide—Vomiting—Mitoxantrone—lymphatic system cancer	2.11e-05	0.000344	CcSEcCtD
Ifosfamide—Immune system disorder—Methotrexate—lymphatic system cancer	2.11e-05	0.000343	CcSEcCtD
Ifosfamide—Mediastinal disorder—Methotrexate—lymphatic system cancer	2.1e-05	0.000342	CcSEcCtD
Ifosfamide—Rash—Mitoxantrone—lymphatic system cancer	2.1e-05	0.000341	CcSEcCtD
Ifosfamide—Dermatitis—Mitoxantrone—lymphatic system cancer	2.09e-05	0.000341	CcSEcCtD
Ifosfamide—Chills—Methotrexate—lymphatic system cancer	2.09e-05	0.000341	CcSEcCtD
Ifosfamide—Alopecia—Methotrexate—lymphatic system cancer	2.06e-05	0.000335	CcSEcCtD
Ifosfamide—Mental disorder—Methotrexate—lymphatic system cancer	2.04e-05	0.000333	CcSEcCtD
Ifosfamide—Erythema—Methotrexate—lymphatic system cancer	2.03e-05	0.00033	CcSEcCtD
Ifosfamide—Malnutrition—Methotrexate—lymphatic system cancer	2.03e-05	0.00033	CcSEcCtD
Ifosfamide—Nausea—Vincristine—lymphatic system cancer	2.03e-05	0.00033	CcSEcCtD
Ifosfamide—Nausea—Mitoxantrone—lymphatic system cancer	1.97e-05	0.000322	CcSEcCtD
Ifosfamide—Vision blurred—Methotrexate—lymphatic system cancer	1.91e-05	0.000311	CcSEcCtD
Ifosfamide—Ill-defined disorder—Methotrexate—lymphatic system cancer	1.88e-05	0.000307	CcSEcCtD
Ifosfamide—Anaemia—Methotrexate—lymphatic system cancer	1.88e-05	0.000305	CcSEcCtD
Ifosfamide—Malaise—Methotrexate—lymphatic system cancer	1.83e-05	0.000298	CcSEcCtD
Ifosfamide—Vertigo—Methotrexate—lymphatic system cancer	1.82e-05	0.000297	CcSEcCtD
Ifosfamide—Leukopenia—Methotrexate—lymphatic system cancer	1.82e-05	0.000296	CcSEcCtD
Ifosfamide—Cough—Methotrexate—lymphatic system cancer	1.77e-05	0.000288	CcSEcCtD
Ifosfamide—Convulsion—Methotrexate—lymphatic system cancer	1.76e-05	0.000286	CcSEcCtD
Ifosfamide—Chest pain—Methotrexate—lymphatic system cancer	1.73e-05	0.000281	CcSEcCtD
Ifosfamide—Arthralgia—Methotrexate—lymphatic system cancer	1.73e-05	0.000281	CcSEcCtD
Ifosfamide—Myalgia—Methotrexate—lymphatic system cancer	1.73e-05	0.000281	CcSEcCtD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	1.72e-05	0.000279	CcSEcCtD
Ifosfamide—Discomfort—Methotrexate—lymphatic system cancer	1.71e-05	0.000278	CcSEcCtD
Ifosfamide—Confusional state—Methotrexate—lymphatic system cancer	1.67e-05	0.000272	CcSEcCtD
Ifosfamide—Anaphylactic shock—Methotrexate—lymphatic system cancer	1.66e-05	0.00027	CcSEcCtD
Ifosfamide—Infection—Methotrexate—lymphatic system cancer	1.65e-05	0.000268	CcSEcCtD
Ifosfamide—Nervous system disorder—Methotrexate—lymphatic system cancer	1.62e-05	0.000264	CcSEcCtD
Ifosfamide—Thrombocytopenia—Methotrexate—lymphatic system cancer	1.62e-05	0.000264	CcSEcCtD
Ifosfamide—Skin disorder—Methotrexate—lymphatic system cancer	1.61e-05	0.000262	CcSEcCtD
Ifosfamide—Hyperhidrosis—Methotrexate—lymphatic system cancer	1.6e-05	0.000261	CcSEcCtD
Ifosfamide—Anorexia—Methotrexate—lymphatic system cancer	1.58e-05	0.000257	CcSEcCtD
Ifosfamide—Hypotension—Methotrexate—lymphatic system cancer	1.55e-05	0.000252	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	1.51e-05	0.000246	CcSEcCtD
Ifosfamide—Paraesthesia—Methotrexate—lymphatic system cancer	1.49e-05	0.000242	CcSEcCtD
Ifosfamide—Dyspnoea—Methotrexate—lymphatic system cancer	1.48e-05	0.00024	CcSEcCtD
Ifosfamide—Somnolence—Methotrexate—lymphatic system cancer	1.47e-05	0.00024	CcSEcCtD
Ifosfamide—Decreased appetite—Methotrexate—lymphatic system cancer	1.44e-05	0.000234	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	1.43e-05	0.000233	CcSEcCtD
Ifosfamide—Fatigue—Methotrexate—lymphatic system cancer	1.43e-05	0.000233	CcSEcCtD
Ifosfamide—Pain—Methotrexate—lymphatic system cancer	1.42e-05	0.000231	CcSEcCtD
Ifosfamide—Feeling abnormal—Methotrexate—lymphatic system cancer	1.36e-05	0.000222	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	1.35e-05	0.000221	CcSEcCtD
Ifosfamide—Urticaria—Methotrexate—lymphatic system cancer	1.32e-05	0.000214	CcSEcCtD
Ifosfamide—Abdominal pain—Methotrexate—lymphatic system cancer	1.31e-05	0.000213	CcSEcCtD
Ifosfamide—Body temperature increased—Methotrexate—lymphatic system cancer	1.31e-05	0.000213	CcSEcCtD
Ifosfamide—Hypersensitivity—Methotrexate—lymphatic system cancer	1.22e-05	0.000199	CcSEcCtD
Ifosfamide—Asthenia—Methotrexate—lymphatic system cancer	1.19e-05	0.000193	CcSEcCtD
Ifosfamide—Pruritus—Methotrexate—lymphatic system cancer	1.17e-05	0.000191	CcSEcCtD
Ifosfamide—Diarrhoea—Methotrexate—lymphatic system cancer	1.13e-05	0.000185	CcSEcCtD
Ifosfamide—Dizziness—Methotrexate—lymphatic system cancer	1.1e-05	0.000178	CcSEcCtD
Ifosfamide—Vomiting—Methotrexate—lymphatic system cancer	1.05e-05	0.000171	CcSEcCtD
Ifosfamide—Rash—Methotrexate—lymphatic system cancer	1.04e-05	0.00017	CcSEcCtD
Ifosfamide—Dermatitis—Methotrexate—lymphatic system cancer	1.04e-05	0.00017	CcSEcCtD
Ifosfamide—Nausea—Methotrexate—lymphatic system cancer	9.84e-06	0.00016	CcSEcCtD
